BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28010166)

  • 1. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
    Dash RP; Babu RJ; Srinivas NR
    Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
    Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
    Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
    Scheen AJ
    Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
    Odaka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():393-8. PubMed ID: 12387024
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
    Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
    Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
    Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
    Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
    Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
    Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
    Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure?
    Nagai Y; Hayakawa T; Abe T; Nomura G
    Diabetes Care; 2000 Nov; 23(11):1703. PubMed ID: 11092296
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of voglibose in type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2014 Jun; 15(8):1181-90. PubMed ID: 24798092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
    Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
    Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 18. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.
    DiNicolantonio JJ; Bhutani J; O'Keefe JH
    Open Heart; 2015; 2(1):e000327. PubMed ID: 26512331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis.
    Alssema M; Ruijgrok C; Blaak EE; Egli L; Dussort P; Vinoy S; Dekker JM; Denise Robertson M
    Nutr Diabetes; 2021 Mar; 11(1):11. PubMed ID: 33658478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
    Carlson RF
    Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.